Last edition
News about "Baxfendy"
AstraZeneca Wins US Approval for Baxfendy, First Aldosterone Synthase Inhibitor for Hypertension
AstraZeneca receives US approval for Baxfendy, the first Aldosterone Synthase Inhibitor (ASI) for adults with hypertension, supported by phase 3 BaxHTN trial results showing significant reductions in systolic blood pressure.
Baxfendy | 20/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members